Table 1 Baseline characteristics.

From: Prognostic value of soluble PD-L1 and exosomal PD-L1 in advanced gastric cancer patients receiving systemic chemotherapy

Variables

 

Low

High

 

Low

High

 

sPD-L1

sPD-L1

exoPD-L1

exoPD-L1

n = 99

n = 72

n = 27

p value*

n = 38

n = 61

p value*

Age (years)

Range (37–83)

  

0.059

  

0.208

 < 65

52 (52.5%)

42 (58.3%)

10 (37.0%)

 

23 (60.5%)

29 (47.5%)

 

 ≥ 65

47 (47.5%)

30 (41.7%)

17 (63.0%)

 

15 (39.5%)

32 (52.5%)

 

Sex

   

0.149

  

0.079

 Male

70 (70.7%)

48 (66.7%)

22 (81.5%)

 

23 (60.5%)

47 (77.0%)

 

 Female

29 (29.3%)

24 (33.3%)

5 (18.5%)

 

15 (39.5%)

14 (23.0%)

 

ECOG PS

   

0.701

  

0.729

 0, 1

90 (90.9%)

66 (91.7%)

24 (88.9%)

 

34 (89.5%)

56 (91.8%)

 

 2

9 (9.1%)

6 (8.3%)

3 (11.1%)

 

4 (10.5%)

5 (8.2%)

 

Differentiation

   

0.113

  

0.343

 Well to moderate

26 (26.3%)

22 (30.6%)

4 (14.8%)

 

12 (31.6%)

14 (23.0%)

 

 Poor

73 (73.7%)

50 (69.4%)

23 (85.2%)

 

26 (68.4%)

47 (77.0%)

 

HER2

   

0.341

  

0.912

 Positive

10 (10.1%)

6 (8.3%)

4 (14.8%)

 

4 (10.5%)

6 (9.8%)

 

 Negative

89 (89.9%)

66 (91.7%)

23 (85.2%)

 

34 (89.5%)

55 (90.2%)

 

Disease status

   

0.058

  

0.476

 Locally advanced

9 (9.1%)

9 (12.5%)

0 (0.0%)

 

2 (5.3%)

7 (11.5%)

 

 Recurrent or metastatic

90 (90.9%)

63 (87.5%)

27 (100.0%)

 

36 (94.7%)

54 (88.5%)

 

Peritoneal seeding

   

0.837

  

0.130

 Yes

53 (53.5%)

39 (54.2%)

14 (51.9%)

 

24 (63.2%)

29 (47.5%)

 

 No

46 (46.5%)

33 (45.8%)

13 (48.1%)

 

14 (36.8%)

32 (52.5%)

 

No. of metastatic sites

   

0.036

  

0.293

 ≥ 2

35 (35.4%)

21 (29.2%)

14 (51.9%)

 

11 (28.9%)

24 (39.3%)

 

 < 2

64 (64.6%)

51 (70.8%)

13 (48.1%)

 

27 (71.1%)

37 (60.7%)

 

CEA (ng/mL)

   

0.007

  

0.349

 > 5

31 (31.3%)

17 (23.6%)

14 (51.9%)

 

14 (36.8%)

17 (27.9%)

 

 ≤ 5

68 (68.7%)

55 (76.4%)

13 (48.1%)

 

24 (63.2%)

44 (72.1%)

 

CA 19-9 (U/mL)

   

0.492

  

0.535

 > 37

35 (35.4%)

24 (33.3%)

11 (40.7%)

 

12 (31.6%)

23 (37.7%)

 

 ≤ 37

64 (64.6%)

48 (66.7%)

16 (59.3%)

 

26 (68.4%)

38 (62.3%)

 

Tissue PD-L1

   

0.877

  

0.058

 CPS ≥ 10

44 (44.4%)

31 (43.1%)

13 (48.1%)

 

21 (55.3%)

23 (37.7%)

 

 CPS < 10

46 (46.5%)

34 (45.8%)

12 (44.4%)

 

12 (31.6%)

34 (55.7%)

 

 Undetermined

9 (9.1%)

7 (9.7%)

2 (7.4%)

 

5 (13.2%)

4 (6.6%)

 
  1. Data are n (%). *p value from Chi-square test or Fisher's exact test for categorical variables.
  2. HER2 human epidermal growth factor receptor 2, CEA carcinoembryonic antigen, CA 19-9 Cancer antigen 19-9, PD-L1 programmed death ligand 1, CPS combined positive score.
  3. Significant p-values < 0.05 are shown in bold.
Back to article page